News
In this analysis, we explore the potential upside for Merck despite its short-term hurdles.
Former Memphis Grizzlies fan favorite Yuki Kawamura will now be looking for his next opportunity with the Chicago Bulls ...
The CDC’s ACIP has blessed Merck’s new RSV shot Enflonsia, but the decision was not resounding from Robert F. Kennedy Jr.’s new panel of experts.
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29RAHWAY, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its ...
RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.
Merck’s potential for upside hinges on its ability to execute on several key fronts: successfully advancing its pipeline, expanding geographically, and making strategic acquisitions.
Merck & Co., Inc. (NYSE: MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention ...
RAHWAY, N.J., June 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR ...
Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.
Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received positive topline results ...
Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results